Deciphera Pharmaceuticals (NASDAQ: DCPH)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-01 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.600 | ||||||
REV | 32.494M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) through any online brokerage.
Other companies in Deciphera Pharmaceuticals’s space includes: Avidity Biosciences (NASDAQ:RNA), Valneva (NASDAQ:VALN), Chinook Therapeutics (NASDAQ:KDNY), Replimune Group (NASDAQ:REPL) and FibroGen (NASDAQ:FGEN).
The latest price target for Deciphera Pharmaceuticals (NASDAQ: DCPH) was reported by SVB Leerink on Friday, August 5, 2022. The analyst firm set a price target for 21.00 expecting DCPH to rise to within 12 months (a possible 23.97% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Deciphera Pharmaceuticals (NASDAQ: DCPH) is $16.94 last updated August 9, 2022, 8:00 PM UTC.
There are no upcoming dividends for Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals’s Q3 earnings are confirmed for Tuesday, November 1, 2022.
There is no upcoming split for Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.